162 related articles for article (PubMed ID: 25504667)
1. Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients.
Ciccarelli N; Grima P; Fabbiani M; Baldonero E; Borghetti A; Milanini B; Limiti S; Colafigli M; Tamburrini E; Cauda R; De Luca A; Di Giambenedetto S
Antivir Ther; 2015; 20(4):433-40. PubMed ID: 25504667
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients.
Fabbiani M; Ciccarelli N; Tana M; Farina S; Baldonero E; Di Cristo V; Colafigli M; Tamburrini E; Cauda R; Silveri MC; Grima P; Di Giambenedetto S
HIV Med; 2013 Mar; 14(3):136-44. PubMed ID: 22994586
[TBL] [Abstract][Full Text] [Related]
3. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
[TBL] [Abstract][Full Text] [Related]
4. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
[TBL] [Abstract][Full Text] [Related]
5. Risk of non-AIDS-defining events among HIV-infected patients not yet on antiretroviral therapy.
Zhang S; van Sighem A; Kesselring A; Gras L; Prins JM; Hassink E; Kauffmann R; Richter C; de Wolf F; Reiss P;
HIV Med; 2015 May; 16(5):265-72. PubMed ID: 25604160
[TBL] [Abstract][Full Text] [Related]
6. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
[TBL] [Abstract][Full Text] [Related]
7. Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia.
Ciccarelli N; Fabbiani M; Colafigli M; Trecarichi EM; Silveri MC; Cauda R; Murri R; De Luca A; Di Giambenedetto S
Antivir Ther; 2013; 18(2):153-60. PubMed ID: 23486721
[TBL] [Abstract][Full Text] [Related]
8. Correlations between computerized battery testing and a memory questionnaire for identification of neurocognitive impairment in HIV type 1-infected subjects on stable antiretroviral therapy.
Garvey LJ; Yerrakalva D; Winston A
AIDS Res Hum Retroviruses; 2009 Aug; 25(8):765-9. PubMed ID: 19678764
[TBL] [Abstract][Full Text] [Related]
9. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
10. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
[TBL] [Abstract][Full Text] [Related]
11. Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort.
Baker JV; Henry WK; Patel P; Bush TJ; Conley LJ; Mack WJ; Overton ET; Budoff M; Hammer J; Carpenter CC; Hodis HN; Brooks JT;
Clin Infect Dis; 2011 Oct; 53(8):826-35. PubMed ID: 21860012
[TBL] [Abstract][Full Text] [Related]
12. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs.
Le Moing V; Thiébaut R; Chêne G; Sobel A; Massip P; Collin F; Meyohas M; Al Kaïed F; Leport C; Raffi F;
HIV Med; 2007 Apr; 8(3):156-63. PubMed ID: 17461859
[TBL] [Abstract][Full Text] [Related]
13. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
Castagna A; Galli L; Torti C; D'Arminio Monforte A; Mussini C; Antinori A; Cozzi-Lepri A; Ladisa N; De Luca A; Seminari E; Gianotti N; Lazzarin A
Antivir Ther; 2010; 15(2):165-75. PubMed ID: 20386071
[TBL] [Abstract][Full Text] [Related]
14. Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy.
Garvey L; Surendrakumar V; Winston A
HIV Clin Trials; 2011; 12(6):333-8. PubMed ID: 22189152
[TBL] [Abstract][Full Text] [Related]
15. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
16. Liver fibrosis is associated with cognitive impairment in HIV-positive patients.
Ciccarelli N; Fabbiani M; Grima P; Limiti S; Fanti I; Mondi A; Gagliardini R; D'Avino A; Borghetti A; Cauda R; Di Giambenedetto S
J Int AIDS Soc; 2014; 17(4 Suppl 3):19722. PubMed ID: 25397468
[TBL] [Abstract][Full Text] [Related]
17. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy.
Hulgan T; Shepherd BE; Raffanti SP; Fusco JS; Beckerman R; Barkanic G; Sterling TR
J Infect Dis; 2007 Feb; 195(3):425-31. PubMed ID: 17205482
[TBL] [Abstract][Full Text] [Related]
18. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
[TBL] [Abstract][Full Text] [Related]
19. Do HIV type 1 RNA levels provide additional prognostic value to CD4(+) T lymphocyte counts in patients with advanced HIV type 1 infection?
Arduino JM; Fischl MA; Stanley K; Collier AC; Spiegelman D
AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1099-105. PubMed ID: 11522179
[TBL] [Abstract][Full Text] [Related]
20. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression.
Moore RD; Keruly JC
Clin Infect Dis; 2007 Feb; 44(3):441-6. PubMed ID: 17205456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
